


PRODUCT INFORMATION



BCTC

Item No. 10006309

CAS Registry No.: 393514-24-4
Formal Name: 4-(3-chloro-2-pyridinyl)-N-[4-(1,1-dimethylethyl)phenyl]-1-piperazinecarboxamide
MF: C₂₀H₂₅ClN₄O
FW: 372.9
Purity: ≥98%
UV/Vis.: λ_{max}: 247 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

BCTC is supplied as a crystalline solid. A stock solution may be made by dissolving the BCTC in the solvent of choice. BCTC is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of BCTC in these solvents is approximately 10, 12.5, and 20 mg/ml, respectively.

BCTC is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, BCTC should first be dissolved in DMF and then diluted with the aqueous buffer of choice. BCTC has a solubility of approximately 0.25 mg/ml in a 1:3 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

The vanilloid receptor 1 (TRPV1) is a ligand-gated ion channel highly expressed on primary nociceptive neurons that respond to a variety of noxious stimuli, including heat, acid, and other chemical irritants. Because disruptions in TRPV1 activity cause reduced thermal nociception and hyperalgesia, this receptor is considered to be a useful target for the discovery of novel analgesics. BCTC is a potent TRPV1 antagonist that inhibits capsaicin-induced and acid-induced activation of rat TRPV1 with IC₅₀ values of 35 and 6 nM, respectively.^{1,2}

References

1. Valenzano, K.J., Grant, E.R., Wu, G., *et al.* N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl) tetrahydropyrazine-1 (2H)-carbox-amide (BCTC), a novel orally effective vanilloid receptor 1 antagonist with analgesic properties: I. *In vitro* characterization and pharmacokinetic properties. *J. Pharmacol. Exp. Ther.* **306**(1), 377-386 (2003).
2. Gavva, N.R., Tamir, R., Klionsky, L., *et al.* Proton activation does not alter antagonist interaction with the capsaicin-binding pocket of TRPV1. *Mol. Pharmacol.* **68**(6), 1524-1533 (2005).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/10/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM